Oldwick, New Jersey-based Provention Bio’s PRV-6527, which was licensed from Johnson & Johnson company Janssen, failed in a mid-stage clinical trial.

Japan’s Takeda Pharmaceutical presented more data from the company’s Phase IIIb head-to-head VARSITY clinical trial of Entyvio compared to AbbVie’s Humira in ulcerative colitis.

Takeda Pharmaceutical Company Limited and Portal Instruments announced a collaboration to develop and commercialize Portal’s needle-free drug delivery device for potential use with Takeda’s investigational or approved biologic medicines.